Download PDF
Thromb Haemost 1970; 23(01): 019-025
DOI: 10.1055/s-0038-1654115
Originalarbeiten – Original Articles – Travaux Originaux
Schattauer GmbH

A Simple Procedure for Accurate Quantitation of Factor VIII Inhibitors

Daphne Tse B. S.,
1   Research Division, HYLAND Division Travenol Laboratories, Inc., Costa Mesa, California 92626
,
L Fekete B. S.
1   Research Division, HYLAND Division Travenol Laboratories, Inc., Costa Mesa, California 92626
,
E Shanbrom M. D.
1   Research Division, HYLAND Division Travenol Laboratories, Inc., Costa Mesa, California 92626
› Author Affiliations
Further Information

Publication History

Publication Date:
27 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

A simple assay for quantitative determination of factor VIII (AHF) inhibitors has been developed. The presence of AHF inhibitor is confirmed by determining clotting time in serial dilutions of patient’s plasma. The amount of inhibitor is then quantitat-ed by adding known units of human AHF concentrate (1 to 100 units/ml) to plasma until neutralization occurs. The neutralization point is defined as that level of AHF concentrate which clots the patient’s plasma in the same time as the control plasma (inhibitor-free) would clot in the presence of 1 unit of AHF concentrate. (This point, minus the initial 1 unit/ml, gives the titer of inhibitor present (units/ml). The dosage of AHF concentrate required to overcome the inhibitor and raise the free circulating AHF to the desired theoretical level is then calculated from the known titer of inhibitor. This method has been evaluated by assays of 75 samples from 22 patients with acquired or induced AHF inhibitors. In vivo plasma AHF activity correlated well with the calculated in vitro values. The assay provides reliable and accurate quantitation of factor VIII inhibitors enabling precise calculation of effective AHF dosage and monitoring of therapeutic response. The assay can be readily adapted to quantitation of other clotting factor inhibitors.

 

  • References

  • 1 Roberts H. R, Scales M. G, Madison J. T, Webster W. P, Penick G. D. A clinical and experimental study of acquired inhibitors to factor VIII. Blood 26: 805 1965;
    PubMedSearch in Google Scholar
  • 2 Brinkhous K. M, Shanbrom E, Roberts H. R, Webster W. P, Fekete L, Wagner R. H. A new high-potency glycine-precipitated antihemophilic factor (AHF) concentrate. Treatment of classical hemophilia and hemophilia with inhibitors. J. Amer. med. Ass 205: 613 1968;
    CrossrefPubMedSearch in Google Scholar
  • 3 Mc Lester W, Wagner R. H. Antibody to antihemophilic factor und lack of reaction with hemophilic plasma. Amer. J. Physiol 208: 499 1965;
    PubMedSearch in Google Scholar
  • 4 Hardisty R. M, MacPherson J. G. A one-stage Factor VIII (antihaemophilic globulin) assay and its use on venous and capillary plasma. Thrombos. Diathes. haemorrh. (Stuttg.) 7: 215 1962;
    PubMedSearch in Google Scholar
  • 5 Proctor R. R, Rapaport S. I. The partial thromboplastin time with kaolin: A simple screening test for first-stage plasma clotting factor deficiencies. Amer. J. clin. Path 36: 212 1961;
    PubMedSearch in Google Scholar
  • 6 Shanbrom E, Thelin G. M. Experimental prophylaxis of severe hemophilia with a factor VIII concentrate. J. A. M. A 208: 1853 1969;
    CrossrefPubMedSearch in Google Scholar
  • 7 Abildgaard C. F, Simone J. V, Corrigan J. J, Seeler R. A, Edelstein G, Vanderheiden J, Schulman I. Treatment of hemophilia with glycine-precipitated factor VIII. New Engl. J. Med 275: 471 1966;
    CrossrefPubMedSearch in Google Scholar
  • 8 Abildgaard G, Schulman I. Specific therapy of hemophilia. Panel discussion before the 5th Congress of World Federation of Hemophilia, International Hemophilia Symposium, Montreal, Canada, August 26, 1968.
    PubMed
  • 9 Bishop R, Fekete L, Shanbrom E. A new technic for estimating components of the fibrinolytic system. Abstract : Federation of American Societies for Experimental Biology, Atlantic City N. J., April 14, 1969. Vol 28, 321 (1969).
    PubMed